Avalo Therapeutics
AVTX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +144.4% in FY2025
Garry Neil, M.D. is the CEO of Avalo Therapeutics and was paid $3.8M in FY2025 (Dec), down 47%.
Pay$100 in the stock at the end of FY21 → $0
Executives3
See all- 1Garry Neil, M.D.Chief Executive Officer, President and principal executive officerFY2025
- 2Taylor BoydChief Business OfficerFY2025
- 3Mittle Doyle, M.D, FACRChief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAvalo Therapeutics paid its 3 named executives $8.8M in total in FY2025 (Dec). CEO Garry Neil, M.D. was paid $3.8M of that.
| Name | |||
|---|---|---|---|
| Garry Neil, M.D.Chief Executive Officer, President and principal executive officer | |||
| Taylor BoydChief Business Officer | Not disclosed | ||
| Mittle Doyle, M.D, FACRChief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Avalo Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Gilla Kaplan, Ph.D.Director · 5 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Garry Neil, M.D.Director · 3 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 10, 2026 | FY2025 |
| Annual report | 10-K | Mar 23, 2026 | FY2025 |
| Proxy statement | DEF 14A | May 1, 2025 | FY2024 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jun 27, 2024 | FY2023 |
| Annual report | 10-K | Mar 29, 2024 | FY2023 |
